First quarter 2024 results
First quarter 2024 results were reviewed by management during a conference call with the financial community on April 25th. The presentation was followed by a Q&A session.
14:30 - 16:00 CET (8:30am – 10am EST)
Featuring
![Paul Hudson](/optim/dotcom/content-app/events/quaterly-results/2024/2024-q1-2024-results/paul-hudson-featuring_20240425060257.jpg?size=small)
Paul Hudson
Chief Executive Officer
![François Roger](/optim/dotcom/content-app/events/quaterly-results/2024/2024-q1-2024-results/francois-xavier-roger-featuring_20240425060257.jpg?size=small)
François Roger
Chief Financial Officer
![Houman Ashrafian](/optim/dotcom/content-app/events/quaterly-results/2024/2024-q1-2024-results/houman-ashrafian-featuring_20240425060257.jpg?size=small)
Houman Ashrafian
Head of Research and Development
Highlights
Paul Hudson comments on Q1 2024 results
![](/optim/dotcom/content-app/events/quaterly-results/2024/2024-q1-2024-results/bio-paul-hudson.jpg?size=large)
We are off to an excellent start in 2024, delivering on our strategic priorities and a transformation of our portfolio of medicines and vaccines to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth.
![Paul Hudson](/optim/dotcom/content-app/events/quaterly-results/2024/2024-q1-2024-results/bio-paul-hudson.jpg?size=small)
Paul Hudson
Chief Executive Officer